Dermata Therapeutics Announces FDA Feedback On The DMT310 Phase 3 Clinical Development Program In Moderate-To-Severe Acne
Portfolio Pulse from Benzinga Newsdesk
Dermata Therapeutics has received FDA feedback on its DMT310 Phase 3 clinical development program for moderate-to-severe acne. The program will consist of two pivotal trials, STAR-1 and STAR-2, with the first patient enrollment planned for 2H 2023.
June 27, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dermata Therapeutics' DMT310 Phase 3 clinical program for acne treatment receives FDA feedback, with two pivotal trials planned and enrollment starting in 2H 2023.
The FDA feedback on Dermata Therapeutics' DMT310 Phase 3 clinical program is a positive development for the company, as it establishes key elements of the program and delineates a potential regulatory pathway for approval. This news is likely to have a positive short-term impact on DRMA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100